Kristin Jensen

The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.

The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.

The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be pushing values higher, according to one analyst.

Elevidys sales have increased since the FDA chose to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving” treatment landscape.

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.

The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.

Analysts slashed their price targets for the Massachusetts biotech after ‘messy' trial results in alopecia and eczema.

The biotech halted dosing in two study arms after finding instances of pericardial effusion in testing of its drug, which analysts have viewed as a potential threat to Merck's Winrevair.